Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The pyruvate dehydrogenase E1 alpha subunit is encoded by the PDHA1 gene on the X chromosome. It forms part of the heterotetrameric E1 enzyme (with two alpha and two beta subunits), which catalyzes the critical conversion of pyruvate to acetyl-CoA, initiating the TCA cycle and driving cellular respiration. Mutations in this subunit disrupt mitochondrial energy metabolism, leading to inherited metabolic disorders such as PDC deficiency, characterized by lactic acidosis and neurological symptoms[1][3][7]. It is also mechanistically implicated in cancer cell metabolism and serves as a potential pharmacological target in metabolic modulation therapies[2][7].
Dichloroacetate: inhibits pyruvate dehydrogenase kinase, thus activating the pyruvate dehydrogenase complex Thiamine supplementation: increases cofactor affinity in deficiency states
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyruvate dehydrogenase E1 component subunit alpha, mitochondrial (PDHA1).